- PR Newswire•2 months agoEntest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications
Entest BioMedical's (ENTB) wholly owned subsidiary Zander Therapeutics, Inc. announced the filing of a patent application covering composition of matter and methods of use related to molecules identified in their small molecule program that activate and inhibit NR2F6 ('Small Molecule Modulators of NR2F6 Activity for Animals'). NR2F6 is a molecular switch known as an 'orphan nuclear receptor', which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Zander Therapeutics, Inc. has been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize veterinary applications of NR2F6.
- Marketwired•2 years ago
Entest BioMedical Inc. announced today that the Company is currently in discussions to acquire a nanotechnology for the delivery of cancer therapeutics in both animals and humans.
ENTB : Summary for ENTEST BIOMEDICAL COM USD0.001 - Yahoo Finance
Entest Biomedical, Inc. (ENTB)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Bid||2.40 x 500|
|Ask||3.50 x 500|
|Day's Range||0.03 - 0.04|
|52 Week Range||0.01 - 0.09|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|